Released Nov 12, 2024, before the open
10-Q filed Nov 12, 2024, 43 days after period end · 0001171843-24-006248
Q3 2024 · 10-Q
Revenue$0.00$0.00 — vs Q3 2023−100.0% vs Q2 2024
Net Income-$10.48M-$10.48M N/M vs Q3 2023N/M vs Q2 2024
EPS, diluted—
Operating Income-$12,239,000N/M
Operating Cash Flowderived-$11,051,000N/M
Free Cash Flowderived-$11,095,000N/M
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | — |
| Net Income | -$10.48M | -$9.96M | -$11.98M | -$5.98M |
| EPS Diluted | — | — | — | -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR